Full-Life Technologies, a clinical stage radiotherapeutics company with operations in Belgium, Germany, and China, has raised US$150m led by Vivo Capital. Vivo was joined in the financing package, consisting of US$109m in Series D equity and US$41m in debt, by Full-Life’s strategic partner SK Biopharmaceuticals and Chengwei Capital, HSG, Junson Capital, Plaisance, Sky9 Capital, Yunion, as well as other shareholders.
Proceeds will be used to advance the company’s clinical stage assets, including [225Ac]-FL-020 for prostate cancer and [225Ac]-FL-261 for multiple solid tumour indications. By year-end 2026, Full-Life expects to have three differentiated clinical stage programmes. The financing will also facilitate the initiation of GMP-grade 225Ac manufacturing at the company’s plant in Belgium.
Full-Life completed a US$77m financing in September 2025 (US$50m Series C equity and US$27m) debt led by Junson Capital. In 2024, it raised US$63.3m (US$47.3m in Series B equity financing and US$16m debt) led by Prosperity7 Ventures, and in 2022, it completed a US$37m Series A led by Sequoia China.
